Background: Smoking is a well known risk factor for peripheral vascular disease (PVD). The aim of this study is to evaluate the impact of smoking on major clinical outcomes following percutaneous transluminal angioplasty (PTA) for lower extremity occlusive disease as compared with non-smokers. Methods: A total 187 patients (pts) with 350 lesions who underwent PTA for iliofemoral, popliteal and infrapopliteal arterial lesions were enrolled for this study. Pts were divided into two groups; non- smokers (n=127 pts) and smokers (n=60 pts). Procedural outcomes and major clinical outcomes up to 1 year were compared between the two groups. Results: Baseline clinical characteristics were similar between the two groups except that smokers had more males (95% vs. 68.5 %, p<0.001), alcoholics (51.7% vs.14.2%, p<0.001) and dyslipidemia (21.7% vs. 11%, p=0.053), whereas non-smokers were more hypertensive (73.2% vs.56.7%, p=0.024) and had higher Rutherford grade & category. Smokers had more ostial lesions (36.5% vs. 25.7%, p=0.039), longer lesions (90.11짹68.91mm vs. 73.58짹52.5mm9, p=0.022), larger vessel size (4.85짹2.26mm vs. 4.11짹2.27mm, p=0.003) and less De novo lesions (93.7% vs. 99.6, p=0.007). However, despite of worse baseline clinical and procedural characteristics, post-procedural and major clinical outcomes up to 1 year were similar between the two groups (Table). Conclusions: In our study, despite baseline characteristics in smokers, procedural & one year clinical outcomes were similar with those of non-smokers following PTA for lower extremity occlusive disease.